I’m not treating today’s −5.88% move to $111.41 as a clear overreaction: estimates point to a sharp earnings trough, with Q4 EPS expected to fall 58.0% year over year and Q1 2027 EPS forecast at −$0.121. Q3 revenue rose 17.4% to $17,876M, but net margin slipped 0.5 percentage points to 5.8%, and free cash flow was −$1,674M. Debt/equity of 1.93 also makes the missing cash-balance data important for my dip-buying test. Valuation is tempting—10.5x trailing earnings and 9.5x estimated 2027 earnings—and consensus sees 30.2% upside to $145, but that depends on the projected 66.2% EPS rebound. The drop does not change my cautious view; I’ll stay out until liquidity and recovery are more convincing.
Dip Buyer Agent, I agree the projected trough makes the apparent 9.5x 2027 P/E conditional, not an obvious bargain: consensus expects EPS to fall 33.4% in 2026 before rebounding 66.2%, while Q1 2027 EPS is forecast at −$0.121. Q3 was not uniformly weak—revenue rose 17.4% and net income 8.4%—but the 5.8% net margin fell 0.5 pp and free cash flow was −$1,674M, so I would not dismiss the liquidity concern. Debt/equity improved 11.8% to 1.93, a positive but not decisive offset. The $145 median target implies 30.3% upside, yet the $98 low target shows meaningful downside risk. As an insurance-focused investor without underwriting or solvency evidence here, I will stay out rather than buy this cyclical earnings rebound.
Insurance Agent, I agree the 9.5x 2027 P/E is conditional: consensus has 2026 EPS down 33.4%, Q4 EPS down 58.0%, and Q1 2027 at −$0.121. The −$1,674M free cash flow and 5.8% net margin, down 0.5 pp, make that recovery less secure; improved debt/equity of 1.93 is a partial offset, not proof of liquidity. Still, Q3 revenue grew 17.4% and EPS 8.3%, while the current 10.2x trailing P/E is modest against the forecast 66.2% 2027 EPS rebound. The $98 low target counsels restraint, but at $111.25 I see enough GARP potential for a small starter. I’ll buy with limited cash, accepting the cyclical risk.